Skip to main content
Top
Published in: Respiratory Research 1/2020

Open Access 01-12-2020 | Budesonide | Research

HDAC8 inhibitor attenuates airway responses to antigen stimulus through synchronously suppressing galectin-3 expression and reducing macrophage-2 polarization

Authors: Meng-lu Li, Xin-ming Su, Yuan Ren, Xuan Zhao, Ling-fei Kong, Jian Kang

Published in: Respiratory Research | Issue 1/2020

Login to get access

Abstract

Background

This study was to investigate of the mechanism by which histone deacetylase (HDAC) 8 inhibitor ameliorated airway hyperresponsiveness (AHR) and allergic airway inflammation.

Methods

Mice were sensitized and then treated with budesonide (BUD) or PCI-34051 (PCI) prior to exposing to normal saline (NS) or ovalbumin (OVA). The raw264.7 cells were treated with interleukin (IL)-4 and PCI or shRNA alone. Repetitive measurements of enhanced pause (Penh) were executed by increasing concentrations of acetyl-β-methacholine chloride (0 - 50 mg/ml). Cells in bronchoalveolar lavage fluid (BALF) and pathological changes of lungs were examined, respectively. The expression levels of HDAC8, Galecitn (Gal)-3, CD68, CD86, CD163, Arg1 and NOS2 in lungs were measured. Co-regulation of HDAC8 and Gal-3 proteins was observed by immunofluorescence staining and co-immunoprecipitation assay (Co-IP).

Results

Significant increases in Penh and IL-4 level were detected with a large inflammatory infiltrate, comprised predominantly of macrophages and eosinophils, into the BALF in OVA-exposed lungs. HDAC8, Gal-3, CD68, CD86, CD163, Arg1 and NOS2 proteins were over-expressed with the significant changes in the Arg1 and NOS2 mRNA levels in the lungs and the IL-4-treated cells. PCI intervention obviously reduced the counts of CD163+ cells. Furthermore, Gal-3 knockdown suppressed Arg1 expression in the cells. Immunofluorescence staining displayed simultaneous changes in HDAC8 and Gal-3 expression in the investigated samples. Treatment with PCI resulted in synchronous reduction of HDAC8 and Gal-3 expression in the Co-IP complexes.

Conclusions

The HDAC8 inhibitor ameliorates AHR and airway inflammation in animal model of allergic asthma through reducing HDAC8-Gal-3 interaction and M2 macrophage polarization.
Literature
1.
go back to reference Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26:5541–52.PubMedCrossRef Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26:5541–52.PubMedCrossRef
2.
go back to reference Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009;10:32–42.PubMedPubMedCentralCrossRef Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009;10:32–42.PubMedPubMedCentralCrossRef
3.
go back to reference Van den Wyngaert I, de Vries W, Kremer A, Neefs J, Verhasselt P, Luyten WH, et al. Cloning and characterization of human histone deacetylase 8. FEBS Lett. 2000;478:77–83.PubMedCrossRef Van den Wyngaert I, de Vries W, Kremer A, Neefs J, Verhasselt P, Luyten WH, et al. Cloning and characterization of human histone deacetylase 8. FEBS Lett. 2000;478:77–83.PubMedCrossRef
4.
go back to reference Amin SA, Adhikari N, Jha T. Structureeactivity relationships of hydroxamate-based histone deacetylase-8 inhibitors: reality behind anticancer drug discovery. Future Med Chem. 2017;9:2211–37.PubMedCrossRef Amin SA, Adhikari N, Jha T. Structureeactivity relationships of hydroxamate-based histone deacetylase-8 inhibitors: reality behind anticancer drug discovery. Future Med Chem. 2017;9:2211–37.PubMedCrossRef
5.
go back to reference Amin SA, Adhikari N, Jha T. Diverse classes of HDAC8 inhibitors: in search of molecular fingerprints that regulate activity. Future Med Chem. 2018;10:1589–602.PubMedCrossRef Amin SA, Adhikari N, Jha T. Diverse classes of HDAC8 inhibitors: in search of molecular fingerprints that regulate activity. Future Med Chem. 2018;10:1589–602.PubMedCrossRef
6.
go back to reference Chakrabarti A, Oehme I, Witt O, Oliveira G, Sippl W, Romier C, Pierce RJ, Jung M. HDAC8: a multifaceted target for therapeutic interventions. Trends Pharmacol Sci. 2015;36:481–92.PubMedCrossRef Chakrabarti A, Oehme I, Witt O, Oliveira G, Sippl W, Romier C, Pierce RJ, Jung M. HDAC8: a multifaceted target for therapeutic interventions. Trends Pharmacol Sci. 2015;36:481–92.PubMedCrossRef
7.
go back to reference Su XM, Ren Y, Li ML, Zhao X, Kong LF, Kang J. Performance evaluation of histone deacetylases in lungs of mice exposed to ovalbumin aerosol. J Physiol Pharmacol. 2018;69:265–73. Su XM, Ren Y, Li ML, Zhao X, Kong LF, Kang J. Performance evaluation of histone deacetylases in lungs of mice exposed to ovalbumin aerosol. J Physiol Pharmacol. 2018;69:265–73.
8.
go back to reference Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, et al. Decreased histone Deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005;352:1967–76.PubMedCrossRef Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, et al. Decreased histone Deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005;352:1967–76.PubMedCrossRef
9.
go back to reference Bosnar M, Ergovic G, Hrvacic B, et al. The histone-deacetylase-8 selective inhibitor PCI-34051 enhances IFN-λ production in vitro and reduces inflammation in mouse models of rhinoviral infection and rhinovirus-induced exacerbations of asthma in vivo. Eur Respir J. 2013;42:1972. Bosnar M, Ergovic G, Hrvacic B, et al. The histone-deacetylase-8 selective inhibitor PCI-34051 enhances IFN-λ production in vitro and reduces inflammation in mouse models of rhinoviral infection and rhinovirus-induced exacerbations of asthma in vivo. Eur Respir J. 2013;42:1972.
11.
go back to reference Cassol E, Cassetta L, Rizzi C, Alfano M, Poli G. M1 and M2a polarization of human monocyte-derived macrophages inhibits HIV-1 replication by distinct mechanisms. J Immunol. 2009;182:6237–46.PubMedCrossRef Cassol E, Cassetta L, Rizzi C, Alfano M, Poli G. M1 and M2a polarization of human monocyte-derived macrophages inhibits HIV-1 replication by distinct mechanisms. J Immunol. 2009;182:6237–46.PubMedCrossRef
12.
go back to reference Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000;164:6166–73.PubMedCrossRef Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000;164:6166–73.PubMedCrossRef
14.
go back to reference Sciacchitano S, Lavra L, Ulivieri A, Magi F, De Francesco GP, Bellotti C, Salehi LB, Ricci A. Galectin-3: one molecule for an alphabet of diseases, from a to Z. Int J Mol Sci. 2018;19:379.PubMedCentralCrossRef Sciacchitano S, Lavra L, Ulivieri A, Magi F, De Francesco GP, Bellotti C, Salehi LB, Ricci A. Galectin-3: one molecule for an alphabet of diseases, from a to Z. Int J Mol Sci. 2018;19:379.PubMedCentralCrossRef
15.
go back to reference Zuberi RI, Hsu DK, et al. Critical role for Galectin-3 in airway inflammation and bronchial Hyperresponsiveness in a murine model of asthma. Am J Pathol. 2004;165:2045–53.PubMedPubMedCentralCrossRef Zuberi RI, Hsu DK, et al. Critical role for Galectin-3 in airway inflammation and bronchial Hyperresponsiveness in a murine model of asthma. Am J Pathol. 2004;165:2045–53.PubMedPubMedCentralCrossRef
16.
go back to reference Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia. 2008;22:1026–34.PubMedCrossRef Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia. 2008;22:1026–34.PubMedCrossRef
17.
go back to reference Balasubramanian S, Steggerda S, Sirisawad M, Schreeder M, Doiron L, Buggy JJ. The histone Deacetylase-8 (HDAC8) selective inhibitor PCI-34051 decreases Interleukin-1 Beta secretion in vitro and reduces inflammation in vivo. Blood. 2008;112:2581.CrossRef Balasubramanian S, Steggerda S, Sirisawad M, Schreeder M, Doiron L, Buggy JJ. The histone Deacetylase-8 (HDAC8) selective inhibitor PCI-34051 decreases Interleukin-1 Beta secretion in vitro and reduces inflammation in vivo. Blood. 2008;112:2581.CrossRef
18.
go back to reference Lopez G, Bill KL, Bid HK, Braggio D, Constantino D, Prudner B, et al. HDAC8, a potential therapeutic target for the treatment of malignant peripheral nerve sheath tumors (MPNST). PLoS One. 2015;10:e0133302.PubMedPubMedCentralCrossRef Lopez G, Bill KL, Bid HK, Braggio D, Constantino D, Prudner B, et al. HDAC8, a potential therapeutic target for the treatment of malignant peripheral nerve sheath tumors (MPNST). PLoS One. 2015;10:e0133302.PubMedPubMedCentralCrossRef
19.
go back to reference Hsieh CL, Ma HP, Su CM, Chang YJ, Hung WY, Ho YS, et al. Alterations in histone deacetylase 8 lead to cell migration and poor prognosis in breast cancer. Life Sci. 2016;151:7–14.PubMedCrossRef Hsieh CL, Ma HP, Su CM, Chang YJ, Hung WY, Ho YS, et al. Alterations in histone deacetylase 8 lead to cell migration and poor prognosis in breast cancer. Life Sci. 2016;151:7–14.PubMedCrossRef
21.
go back to reference McMillan SJ, Xanthou G, Lloyd CM. Therapeutic administration of budesonide ameliorates allergen-induced airway remodelling. Clin Exp Allergy. 2005;35:388–96.PubMedPubMedCentralCrossRef McMillan SJ, Xanthou G, Lloyd CM. Therapeutic administration of budesonide ameliorates allergen-induced airway remodelling. Clin Exp Allergy. 2005;35:388–96.PubMedPubMedCentralCrossRef
22.
go back to reference Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen GL, Irvin CG, et al. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med. 1997;156:766–75.PubMedCrossRef Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen GL, Irvin CG, et al. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med. 1997;156:766–75.PubMedCrossRef
23.
go back to reference Fricker M, Gibson PD. Macrophage dysfunction in the pathogenesis and treatment of asthma. Eur Respir J. 2017;50:1700196.PubMedCrossRef Fricker M, Gibson PD. Macrophage dysfunction in the pathogenesis and treatment of asthma. Eur Respir J. 2017;50:1700196.PubMedCrossRef
24.
go back to reference Khabbazi S, Goumon Y, Parat MO. Morphine modulates Interleukin-4- or breast Cancer cell-induced pro-metastatic activation of macrophages. Sci Rep. 2015;5:11389.PubMedPubMedCentralCrossRef Khabbazi S, Goumon Y, Parat MO. Morphine modulates Interleukin-4- or breast Cancer cell-induced pro-metastatic activation of macrophages. Sci Rep. 2015;5:11389.PubMedPubMedCentralCrossRef
26.
go back to reference Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000;161:1720–45.PubMedCrossRef Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000;161:1720–45.PubMedCrossRef
27.
go back to reference Kumar RK, Herbert C, Foster PS. The “classical” ovalbumin challenge model of asthma in mice. Curr Drug Targets. 2008;9:485–94.PubMedCrossRef Kumar RK, Herbert C, Foster PS. The “classical” ovalbumin challenge model of asthma in mice. Curr Drug Targets. 2008;9:485–94.PubMedCrossRef
29.
go back to reference Peters-Golden M. The alveolar macrophage the forgotten cell in asthma. Am J Respir Cell Mol Biol. 2004;31:3–7.PubMedCrossRef Peters-Golden M. The alveolar macrophage the forgotten cell in asthma. Am J Respir Cell Mol Biol. 2004;31:3–7.PubMedCrossRef
32.
go back to reference Ren Y, Su X, Kong L, Li M, Zhao X, Yu N, Kang J. Therapeutic effects of histone deacetylase inhibitors in a murine asthma model. Inflamm Res. 2016;65:995–1008.PubMedPubMedCentralCrossRef Ren Y, Su X, Kong L, Li M, Zhao X, Yu N, Kang J. Therapeutic effects of histone deacetylase inhibitors in a murine asthma model. Inflamm Res. 2016;65:995–1008.PubMedPubMedCentralCrossRef
33.
go back to reference Rosenberga HF, Druey KM. Eosinophils, galectins, and a reason to breathe. Proc Natl Acad Sci U S A. 2016;113:9139–41.CrossRef Rosenberga HF, Druey KM. Eosinophils, galectins, and a reason to breathe. Proc Natl Acad Sci U S A. 2016;113:9139–41.CrossRef
34.
go back to reference Chávez-Galán L, Olleros ML, Vesin D, Garcia I. Much more than M1 and M2 macrophages, there are also CD169+ and TCR+ macrophages. Front Immunol. 2015;6:263.PubMedPubMedCentral Chávez-Galán L, Olleros ML, Vesin D, Garcia I. Much more than M1 and M2 macrophages, there are also CD169+ and TCR+ macrophages. Front Immunol. 2015;6:263.PubMedPubMedCentral
35.
go back to reference Li W, Katz BP, Spinola SM. Haemophilus ducreyi-induced Interleukin-10 promotes a mixed M1 and M2 activation program in human macrophages. Infect Immun. 2012;80:4426–34.PubMedPubMedCentralCrossRef Li W, Katz BP, Spinola SM. Haemophilus ducreyi-induced Interleukin-10 promotes a mixed M1 and M2 activation program in human macrophages. Infect Immun. 2012;80:4426–34.PubMedPubMedCentralCrossRef
36.
go back to reference Barros MHM, Hauck F, Dreyer JH, Kempkes B, Niedobitek G. Macrophage polarisation: an Immunohistochemical approach for identifying M1 and M2 macrophages. PLoS One. 2013;8:e80908.PubMedPubMedCentralCrossRef Barros MHM, Hauck F, Dreyer JH, Kempkes B, Niedobitek G. Macrophage polarisation: an Immunohistochemical approach for identifying M1 and M2 macrophages. PLoS One. 2013;8:e80908.PubMedPubMedCentralCrossRef
37.
go back to reference Balhara J, Gounni AS. The alveolar macrophages in asthma: a double-edged sword. Mucosal Immunol. 2012;5:605–9.PubMedCrossRef Balhara J, Gounni AS. The alveolar macrophages in asthma: a double-edged sword. Mucosal Immunol. 2012;5:605–9.PubMedCrossRef
38.
go back to reference Jablonski KA, Amici SA, Webb LM, Ruiz-Rosado Jde D. Popovich PG4, Partida-Sanchez S, et al. novel markers to delineate murine M1 and M2 macrophages. PLoS One. 2015;10:e0145342.PubMedPubMedCentralCrossRef Jablonski KA, Amici SA, Webb LM, Ruiz-Rosado Jde D. Popovich PG4, Partida-Sanchez S, et al. novel markers to delineate murine M1 and M2 macrophages. PLoS One. 2015;10:e0145342.PubMedPubMedCentralCrossRef
40.
go back to reference Saradna A, Do DC, Kumar S, Fu QL, Gao P. Macrophage polarization and allergic asthma. Transl Res. 2018;191:1–14.PubMedCrossRef Saradna A, Do DC, Kumar S, Fu QL, Gao P. Macrophage polarization and allergic asthma. Transl Res. 2018;191:1–14.PubMedCrossRef
41.
go back to reference Rath M, Müller I, Kropf P, Closs EI, Munder M. Metabolism via arginase or nitric oxide synthase: two competing arginine pathways in macrophages. Front Immunol. 2014;5:1–10.CrossRef Rath M, Müller I, Kropf P, Closs EI, Munder M. Metabolism via arginase or nitric oxide synthase: two competing arginine pathways in macrophages. Front Immunol. 2014;5:1–10.CrossRef
42.
go back to reference Moreira AP, Cavassani KA, Hullinger R, Rosada RS, Fong DJ, Murray L, et al. Serum amyloid P attenuates M2 macrophage activation and protects against fungal spore-induced allergic airway disease. J Allergy Clin Immunol. 2010;126:712–21.PubMedCrossRef Moreira AP, Cavassani KA, Hullinger R, Rosada RS, Fong DJ, Murray L, et al. Serum amyloid P attenuates M2 macrophage activation and protects against fungal spore-induced allergic airway disease. J Allergy Clin Immunol. 2010;126:712–21.PubMedCrossRef
43.
go back to reference Melgert BN, Oriss TB, Qi Z, Dixon-McCarthy B, Geerlings M, Hylkema MN, et al. Macrophages: regulators of sex differences in asthma? Am J Respir Cell Mol Biol. 2010;42:595–603.PubMedCrossRef Melgert BN, Oriss TB, Qi Z, Dixon-McCarthy B, Geerlings M, Hylkema MN, et al. Macrophages: regulators of sex differences in asthma? Am J Respir Cell Mol Biol. 2010;42:595–603.PubMedCrossRef
44.
go back to reference Girodet PO, Nguyen D, Mancini JD, Hundal M, Zhou X, Israel E, et al. Alternative macrophage activation is increased in asthma. Am J Respir Cell Mol Biol. 2016;55:467–75.PubMedPubMedCentralCrossRef Girodet PO, Nguyen D, Mancini JD, Hundal M, Zhou X, Israel E, et al. Alternative macrophage activation is increased in asthma. Am J Respir Cell Mol Biol. 2016;55:467–75.PubMedPubMedCentralCrossRef
45.
go back to reference Moreira AP, Hogaboam CM. Macrophages in allergic asthma: fine-tuning their pro- and anti-inflammatory actions for disease resolution. J Interf Cytokine Res. 2011;31:485–91.CrossRef Moreira AP, Hogaboam CM. Macrophages in allergic asthma: fine-tuning their pro- and anti-inflammatory actions for disease resolution. J Interf Cytokine Res. 2011;31:485–91.CrossRef
46.
go back to reference Raes G, De Baetselier P, Noël W, Beschin A, Brombacher F, Hassanzadeh GG. Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. J Leukoc Biol. 2002;71:597–602.PubMed Raes G, De Baetselier P, Noël W, Beschin A, Brombacher F, Hassanzadeh GG. Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. J Leukoc Biol. 2002;71:597–602.PubMed
47.
go back to reference Chen H, Jacobson BA, Mason L, Wolf SF, Bowman MR. FIZZ1 potentiates the carbachol-induced tracheal smooth muscle contraction. Eur Respir J. 2010;36:1165–73.PubMedCrossRef Chen H, Jacobson BA, Mason L, Wolf SF, Bowman MR. FIZZ1 potentiates the carbachol-induced tracheal smooth muscle contraction. Eur Respir J. 2010;36:1165–73.PubMedCrossRef
48.
go back to reference Stempin CC, Dulgerian LR, Garrido VV, Cerban FM. Arginase in parasitic infections: macrophage activation, immunosuppression, and intracellular signals. J Biomed Biotechnol. 2010;2010:683485.PubMedCrossRef Stempin CC, Dulgerian LR, Garrido VV, Cerban FM. Arginase in parasitic infections: macrophage activation, immunosuppression, and intracellular signals. J Biomed Biotechnol. 2010;2010:683485.PubMedCrossRef
49.
go back to reference Steinke JW, Borish L. Th2 cytokines and asthma — Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir Res. 2001;2:66–70.PubMedPubMedCentralCrossRef Steinke JW, Borish L. Th2 cytokines and asthma — Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir Res. 2001;2:66–70.PubMedPubMedCentralCrossRef
50.
go back to reference Lane C, Knight D, Burgess S, Franklin P, Horak F, Legg J, et al. Epithelial inducible nitric oxide synthase activity is the major determinant of nitric oxide concentration in exhaled breath. Thorax. 2004;59:757–60.PubMedPubMedCentralCrossRef Lane C, Knight D, Burgess S, Franklin P, Horak F, Legg J, et al. Epithelial inducible nitric oxide synthase activity is the major determinant of nitric oxide concentration in exhaled breath. Thorax. 2004;59:757–60.PubMedPubMedCentralCrossRef
51.
go back to reference Robertson D, Savage K, Reis-Filho JS, Isacke CM. Multiple immunofluorescence labelling of formalin-fixed paraffin-embedded (FFPE) tissue. BMC Cell Biol. 2008;9:13.PubMedPubMedCentralCrossRef Robertson D, Savage K, Reis-Filho JS, Isacke CM. Multiple immunofluorescence labelling of formalin-fixed paraffin-embedded (FFPE) tissue. BMC Cell Biol. 2008;9:13.PubMedPubMedCentralCrossRef
52.
go back to reference Bataille F, Troppmann S, Klebl F, Rogler G, Stoelcker B, Hofstadter F, et al. Multiparameter immunofluorescence on paraffin-embedded tissue sections. Appl Immunohistochem Mol Morphol. 2006;14:225–8.PubMedCrossRef Bataille F, Troppmann S, Klebl F, Rogler G, Stoelcker B, Hofstadter F, et al. Multiparameter immunofluorescence on paraffin-embedded tissue sections. Appl Immunohistochem Mol Morphol. 2006;14:225–8.PubMedCrossRef
53.
go back to reference Frisch J, Houchins JP, Grahek M, Schoephoerster J, Hagen J, Sweet J, et al. Novel multicolor immunofluorescence technique using primary antibodies raised in the same host species. Methods Mol Biol. 2011;717:233–44.PubMedCrossRef Frisch J, Houchins JP, Grahek M, Schoephoerster J, Hagen J, Sweet J, et al. Novel multicolor immunofluorescence technique using primary antibodies raised in the same host species. Methods Mol Biol. 2011;717:233–44.PubMedCrossRef
54.
55.
go back to reference Suojalehto H, Lindström I, Ahonen N, Puustinen A. Proteomic analysis of the airway inflammation in work related asthma. Eur Respir J. 2014;44:408. Suojalehto H, Lindström I, Ahonen N, Puustinen A. Proteomic analysis of the airway inflammation in work related asthma. Eur Respir J. 2014;44:408.
56.
go back to reference Rivas JDL, Fontanillo C. Protein–protein interactions essentials: key concepts to building and analyzing Interactome networks. PLoS Comput Biol. 2010;6:e1000807.CrossRef Rivas JDL, Fontanillo C. Protein–protein interactions essentials: key concepts to building and analyzing Interactome networks. PLoS Comput Biol. 2010;6:e1000807.CrossRef
58.
go back to reference Nair MG, Guild KJ, Artis D. Novel effector molecules in type 2 inflammation: lessons drawn from helminth infection and allergy. J Immunol. 2006;177:1393–9.PubMedCrossRef Nair MG, Guild KJ, Artis D. Novel effector molecules in type 2 inflammation: lessons drawn from helminth infection and allergy. J Immunol. 2006;177:1393–9.PubMedCrossRef
Metadata
Title
HDAC8 inhibitor attenuates airway responses to antigen stimulus through synchronously suppressing galectin-3 expression and reducing macrophage-2 polarization
Authors
Meng-lu Li
Xin-ming Su
Yuan Ren
Xuan Zhao
Ling-fei Kong
Jian Kang
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2020
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-020-1322-5

Other articles of this Issue 1/2020

Respiratory Research 1/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.